Lo scompenso cardiaco: le riammissioni, un problema in parte evitabile?

Similar documents
Talking points included in this deck are for internal/speaker use only, and are not to be distributed.

The role of remote monitoring in preventing readmissions after acute heart failure

Implantierbarer hämodynamischer Monitor bei Herzinsuffizienzpatienten

Philip B. Adamson, MD, FACC

1/28/2016. The Weight is Over! Heart Failure Epidemic. Heart Failure Epidemic. U.S. Census Bureau Projections. Burden on Society

Value of Continuous Monitoring of. Pulmonary Artery Pressures in Heart Failure. Financial Relationship Disclosure. Liviu Klein MD, MS

Treat the Numbers and Not the Patients The Revolution of Pulmonary Artery Pressure Guided Medical Therapy in Heart Failure

Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?

Implementing the CardioMEMS HF System into the Management of Heart Failure Patients

Integration of diagnostic device information to improve patient management

Remote Monitoring of Pulmonary Artery Pressures

LIVE WEBINAR Boston Scientific External Use. Show and Distribute CRM AA-June 2017

ESC Paris Remote monitoring of cardiac rhythm devices: present and future HEART FAILURE

2018 Update on Heart Failure Management. Where we are today.

Management of Acute Heart Failure

Congestive Heart Failure: Turning Failure Into Success. Wednesday, Feb 21, 2018

Ambulatory Monitoring of Pulmonary Artery Pressure: Why and How 18 th Annual San Diego Heart Failure Symposium

Clinical Policy Title: Wireless pulmonary artery pressure monitoring devices for heart failure

Clinical Policy Title: Wireless pulmonary artery pressure monitoring devices for heart failure

Part I: Hemodynamic Monitoring for Heart Failure: Background and Rationale Akshay S. Desai MD, MPH

2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation

Disclosures. Objectives 3/27/2017. Beki Angerstein ACNP DNP FAHA CHFN Director Advanced Practice Summa Health System

The Role of Information Technology in Disease Management: A Case for Heart Failure

Evidence of Baroreflex Activation Therapy s Mechanism of Action

Heart Failure Management: Integration of Device Sensor Data into Clinical Practice

Novel Device Functions for CRT Optimization and Heart Failure Monitoring

Edoardo Gronda UO cardiologia e Ricerca Dipartimento Cardiovascolare IRCCS MultiMedica

Reducing 30-day Rehospitalization for Heart Failure: An Attainable Goal?

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

9/14/2017 HEART FAILURE IN OBS NO RELEVANT DISCLOSURES IRRELEVANT DISCLOSURES OBJECTIVES WHY HEART FAILURE

Conflicts of Interest

Remote Monitoring in Heart Failure

BETTER HEART FAILURE MANAGEMENT FROM THE COMFORT OF YOUR HOME

Heart Failure Guidelines For your Daily Practice

Heart Failure 101 The Basic Principles of Diagnosis & Management

Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;

How might biomarkers and other strategies help establish adequacy of care?

Pearls in Acute Heart Failure Management

A Deep Dive: Using Device Diagnostics to Assist with Patient Management. Karen Donatello, RN, RCIS, CCDS

CARDIOMEMS HF SYSTEM HOW TO STAY ABOVE HEART FAILURE: TALKING TO YOUR PATIENT ABOUT THE

Heart failure and CRT : new topics and evidence in 2015

CARDIOMEMS HF SYSTEM PATIENT MANAGEMENT CLINICAL QUICK GUIDE

Corporate Medical Policy

The right ventricle in chronic heart failure

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Recognizing and Treating Patients with the Cardio-Renal Syndrome

Disclosures. Preventing Heart Failure Re-admissions in Deaths Due to Cardiovascular Disease (United States: ) Heart Failure

New heart failure RCT: Update on BeAT-HF in the US

The Failing Heart in Primary Care

Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting

HFpEF, Mito or Realidad?

Pivotal Role of Renal Function in Acute Heart failure

Updates in Congestive Heart Failure

Proposal to national Health Technology Assessments (Norway)

Designing Systems for Effective Heart Failure Care

Natriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment

Creating Devices for Personalized Health Monitoring: Cardiovascular Monitoring Case Studies

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009

HEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida

Burden of Mitral Regurgitation (MR) in the US Why is This Important?

Acute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra

The Management of Heart Failure after Biventricular Pacing

Heart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA

Ruolo dei Marcatori Bioumorali nello scompenso cardiaco

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:

Medical Management of Acute Heart Failure

Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy

Heart Failure with preserved ejection fraction (HFpEF)

Practical Points in Cardiorenal Syndrome

Follow-up of CRT patients ESC Munich Clinical and biological follow-up of CRT patients

Continuous Monitoring of Intrathoracic Impedance and Right Ventricular Pressures in Patients With Heart Failure

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

WHAT S NEW IN HEART FAILURE

UPDATES IN MANAGEMENT OF HF

This is What I do to Improve CRT Response for CRT Non-Responders

Novel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes

The Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?

Case (Coding Nightmare) Current Dilemmas in Heart Failure : Closing the Gap between Clinical Care and Coding. Current Dilemmas in Heart Failure :

Ejection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction

Incidence, Predictors, and Outcomes of Prosthesis-Patient Mismatch in 62,125 TAVR Patients. An STS/ACC TVT Registry Report

Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT

Summary/Key Points Introduction

Repair or Replacement

The Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities

HFpEF: Pathophysiology & Treatment

Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function:

A Global perspective on Heart Failure: What needs to change? Martin R Cowie London, United Kingdom

Ultrafiltration in Decompensated Heart Failure. Description

LVADS IN AMBULATORY PATIENTS CLASS III PATIENT SHOULD UNDERGO LVAD IMPLANTATION

Overcoming the Cardiorenal Syndrome

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches

Updates in Pulmonary Hypertension Pharmacotherapy. Ziad Sadik PharmD BCPS

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

Accepted Manuscript. Tolvaptan in Acute Heart Failure: Time to Move On. Randall C. Starling, MD MPH, James B. Young, MD

Transcription:

Lo scompenso cardiaco: le riammissioni, un problema in parte evitabile? E. Gronda UO di Cardiologia e Ricerca Clinica IRCCS MultiMedica Dipartimento Cardiovascolare Interaziendale Gruppo MultiMedica

Heart Failure Facts The primary economical and social burden of HF syndrome is hospitalization rate whose costs represent the highest ones ($40B per year in USA) within the entire health care management [1]. Approximately 80% of HF hospital admissions are driven by pulmonary congestion symptoms [2]. 1. 2014 American Heart Association Heart and Stroke Statistics. 2. O'Connor CM J Cardiac Fail 2005; 11: 200-205

Heart Failure Facts Almost 90% of acute decompensated HF patients, after the admittance to the emergency department, receive i.v. loop diuretic as the treatment of choice [3]. Despite therapy more than 50% of hospitalized patients for acute decompensated HF have little or no dyspnea improvement and weight loss after hospital discharge [2,4] 1 3. Wong YW he (ADHERE-EM). Am Heart J. 2013 Aug;166(2):349-56. doi: 10.1016/j.ahj.2013.05.014. Epub 2013 Jul 1. PMID: 23895819 4. Fonarow GC1; ADHERE Scientific Advisory Committee. Rev Cardiovasc Med. 2003;4 Suppl 7:S21-30.

Worsening Outlook After Each HF Admission

Acutely Decompensated Heart Failure Understanding the Mechanisms Insight from Continuous Physiologic Monitoring * Graph adapted from Adamson PB, et al. Curr Heart Fail Reports, 2009.

A COMPASS trial sub-analysis provided evidence of the changing risk of an acute HF event over the spectrum of estimated PA diastolic pressures (epad) levels seen, as opposed to a specific threshold.

Background COMPASS Study This analysis compared chronic intra-cardiac pressures to later HF events and sought a threshold above which higher pressures conferred worse outcomes. Methods and Results The group median for chronic 24-hour epad was 28 mmhg (excluding 7 days before and after events). Despite weight-guided management, events occurred in 100 of 261 (38%) patients. Event risk increased progressively 20% at 18 mmhg 34% at 25 mmhg 56% at 30 mmhg Among patients with baseline day median epad of 25 mmhg, event risk was 1.10/6 mo when they remained chronically 25 mmhg Risk fell to 0.47 when 24-hour pressures declined to 25 mmhg for more than half of the days. (Circ Heart Fail. 2010;3:580-587.)

Cardiomems hf system New technology for an unmet need PA Pressure Sensor on Catheter Delivery System 4.5cm 120cm Patient Home Electronics Unit PA Pressure Database Physician Access Via Secure Website

cardiomems-champion trial

Impact of PA Pressure Guided HF Management on HF Hospitalizations in GDMT Population 43% Relative Risk Reduction [HR 0.57, 95% CI 0.45-0.74, p<0.0001] Number needed to treat: 3 Abraham WT, Adamson PB, Bauman J, et al J Am Coll Cardiol 2015;A-213

Relief of congestion treats the disease, not just the symptoms 57% Relative Risk Reduction [HR 0.43, 95% CI 0.24-0.76, p=0.0026] NNT=7 Abraham WT, Adamson PB, Bauman J, et al J Am Coll Cardiol 2015;A-213

Direct PAP measurement The good Reliable Provides effective decision making index Not infirmed by subjective interpretation The bad Device cost Invasiveness In patients with high pulmonary vascular resistances PAP might not mirror immediate changes in left ventricular filling pressure.

DOT HF (Circulation 2012) OPTILINK-HF (EHJ 2015) 26% of alarms led to intervention

Derivation of baseline lung impedance in chronic heart failure patients: use for monitoring pulmonary congestion and predicting admissions for decompensation SCHOCHAT M J Clin Monit Comput (2015) 29:341 349 (RSMM Company, Tel Aviv, Israel)

The Lung Impedance Dynamic Related To NYHA F. cl. SCHOCHAT M J Clin Monit Comput (2015) 29:341 349

In patients hospitalized for PCE, significant D LIR decrease were recorded 2 weeks before hospitalization in comparison with its level 4 weeks before hospitalization Dispersion of D LIR values at admission showed that there were no hospitalizations due to PCE when D LIR decreased by less than 24 % SCHOCHAT M J Clin Monit Comput (2015) 29:341 349

In the long term (years) the impedance threshold (or D LIR) decreases beyond the pre-specified value (60 Ohms). It means that a certain degree of tolerance develops therefore: more severe pulmonary congestion is required to induce clinical symptoms. This confirms patient adaptation to a higher degree of pulmonarycongestion whose medical status deteriorates progressively as they experience multiple re-hospitalizations due to acute decompensation (see slide). A prespecified D LIR decrease is a powerful predictor for PCE-related hospitalizations and death. In the study patients who experienced higher degrees of long-standing pulmonary congestion (D LIRyear in the range - 30 to - 70 % vs. 0 to - 30 %) had a higher probability for acute decompensation, associated hospitalization and death. Transthoracic Impedance SCHOCHAT M J Clin Monit Comput (2015) 29:341 349

Medtronic CareLink database A retrospective analysis of 146 238 patients Zile M et al. Circ Heart Fail. 2016;9:e002543. DOI: 10.1161/CIRCHEARTFAILURE.115.002543.)

Medtronic CareLink database A retrospective analysis of 146 238 patients Unlike OptiVol fluid index measurements, directly measured Impedance data can provide data regarding changes in mortality (and potentially morbidity) over time.

SCHOCHAT M et al. JCF 2016

SCHOCHAT M et al. JCF 2016

The Impedance Project for Acute HF Prevention Data collected from the Lombardia Regional Administrative Database on the basis of DRG 127 diagnosis or 428.* for each other position:. Patients with a first HF hospital admission in 2014 (from 1/1 to 31/12) n. 27,112. In this HF population the per year risk for repeated HF admission (at least 1 new admission) was 21.95%. The transthoracic impedance measurementperformed routinely at predetermined time interval in euvolemic patients may reduce in half the per year risk of HF hospital readmission in the managed HF population.